Medizinische Universität Graz - Research portal
Department of Internal Medicine
Division of Respiratory Medicine
SCI/PUBMED listed | all typs of publications | all by year and first author | MUG authors |
** = Publications listed in SCI/SSCI/Pubmed
Full paper/article (Journal)
** Fischinger, C; Popp, F; Reichenberger, F; Kneidinger, N; Tiede, R; von, Wulffen, W; Welcker, M
Early detection of RA‑ILD-A novel screening protocol with pulmonary function testing and lung ultrasound : A monocentric cohort study.
Z Rheumatol. 2026;
Doi: 10.1007/s00393-025-01775-0
PubMed
FullText
FullText_MUG
** Lange, B; Brehm, TT; Arend, SM; Arias-Guillén, M; Bakker, M; Berastegui, C; Babiker, M; Charif, R; Duarte, R; Flick, H; Hofland, RW; Ismail, J; Kniepeiss, D; Krepel, J; Krishnan, N; Kuijpers, DL; Kunst, H; van, Leth, F; Lezaic, V; Los-Arcos, I; Machová, J; Milburn, H; Morais, SA; Kon, OM; Osoro-Suarez, C; Pessegueiro, Miranda, H; Pesut, D; Rahman, A; Reischig, T; Sánchez-Montalvá, A; Spohn, HE; Stegenga, MT; de, Vries, APJ; Wagner, D; Wobser, R; Lange, C; Sester, M
Tuberculosis incidence in solid organ transplant recipients in Europe: A multicenter TBnet cohort study.
J Infect. 2025; 92(1): 106668
Doi: 10.1016/j.jinf.2025.106668
Web of Science
PubMed
FullText
FullText_MUG
** Nayak, BB; Bärnthaler, T; Rajesh, R; Teppan, J; Gogg, T; Douschan, P; Kneidinger, N; van, der, Does, AM; Hiemstra, P; Heinemann, A; Böhm, E
Brepocitinib, a selective TYK2/JAK1 inhibitor, mitigates neutrophilic inflammation and glucocorticoid receptor-β expression in COPD.
Am J Physiol Lung Cell Mol Physiol. 2026;
Doi: 10.1152/ajplung.00237.2025
PubMed
FullText
FullText_MUG
** Stoltefuß, S; Leuschner, G; Veit, T; Götschke, J; Milger, K; Kauke, T; Lenoir, A; Kneidinger, N; Behr, J
Assessing health-related quality of life in patients with interstitial lung diseases with and without lung transplantation using the GR-Scale.
BMC Pulm Med. 2026;
Doi: 10.1186/s12890-025-04101-1
PubMed
FullText
FullText_MUG
** Yogeswaran, A; Annis, JS; Fünderich, M; Wilhelm, J; Kiely, DG; Howard, L; Lawrie, A; Wilkins, MR; Balasubramanian, A; Hassoun, PM; Konswa, Z; Eichstaedt, CA; Grünig, E; Sweatt, AJ; Zamanian, RT; Kovacs, G; Olschewski, H; Lichtblau, M; Ulrich, S; Thenappan, T; Al, Ghouleh, I; Chan, SY; Elwing, J; Jose, A; Cannon, J; Pepke-Zaba, J; Frantz, R; Sirenko, Y; Torbas, O; Sahay, S; Zhai, Z; Zhang, Z; Arvanitaki, A; Giannakoulas, G; Frauendorf, M; Williams, PG; Kuronuma, K; Matsubara, H; Ghio, S; Scelsi, L; Sabbour, H; Saleh, K; Anthi, A; Dima, E; Majeed, RW; Ghofrani, HA; Grimminger, F; Tello, K; Cajigas, HR; Brittain, E; Seeger, W, , PVRI, Consortium
Male survival disadvantage in pulmonary hypertension: independent of aetiology, age, disease severity, comorbidities and treatment.
EBioMedicine. 2026; 123: 106063
Doi: 10.1016/j.ebiom.2025.106063
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG